0 0.0038659793814433 0.00711340206185565 0.0103092783505155 0.0204123711340207 0.0434536082474227 0.0457731958762886 0.0571134020618557
Sign Up Today X
Thanks for submitting the form.
Stockreport

UPDATE 2-Amgen to buy Celgene's psoriasis drug Otezla for $13.4 bln in cash [Reuters (UK)]

Amgen Inc. (AMGN)  More Company Research Source: Reuters
Last amgen inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.amgen.com
Amgen to buy Celgene's psoriasis drug Otezla for $13.4 billion in cash - Reuters 2 Min Read (Reuters) - Amgen Inc said on Monday it would buy Celgene Corp’s psoriasis drug Otezla for $13.4 billion in cash, clearing the way for Bristol-Myers Squibb to go ahead with its $74 billion deal for Celgene. Bristol-Myers now expects the Celgene deal to close by 2019 end, pushing Celgene’s shares up 3% before the opening bell. Amgen shares, however, fell as some investors worried that the company was shelling out more-than-expected for the drug. The deal for Otezla and certain related assets and liabilities is valued at $11.2 billion, net of the present value of $2.2 billion in future cash tax benefits. Bristol-Myers in June offered to sell Otezla, with an analyst valuing a deal for the drug at about $9 billion. RBC Capital Markets analyst Brian Abrahams, who had earlier said that Otezla was a better fit for Gilead Sciences Inc, also pointed to the high price that Amgen was offering. Otezla brou [Read more]
IMPACT SNAPSHOT EVENT TIME: AMGN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
AMGN alerts
from News Quantified
AMGN
NEWS
AMGN
Earnings
AMGN
Analyst Actions
AMGN
SEC Filings
Stockreport

UPDATE 2-Amgen to buy Celgene's psoriasis drug Otezla for $13.4 bln in cash [Reuters (UK)]

Amgen Inc.  (AMGN) 
More Company Research Source: Reuters
Last amgen inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.amgen.com
Amgen to buy Celgene's psoriasis drug Otezla for $13.4 billion in cash - Reuters 2 Min Read (Reuters) - Amgen Inc said on Monday it would buy Celgene Corp’s psoriasis drug Otezla for $13.4 billion in cash, clearing the way for Bristol-Myers Squibb to go ahead with its $74 billion deal for Celgene. Bristol-Myers now expects the Celgene deal to close by 2019 end, pushing Celgene’s shares up 3% before the opening bell. Amgen shares, however, fell as some investors worried that the company was shelling out more-than-expected for the drug. The deal for Otezla and certain related assets and liabilities is valued at $11.2 billion, net of the present value of $2.2 billion in future cash tax benefits. Bristol-Myers in June offered to sell Otezla, with an analyst valuing a deal for the drug at about $9 billion. RBC Capital Markets analyst Brian Abrahams, who had earlier said that Otezla was a better fit for Gilead Sciences Inc, also pointed to the high price that Amgen was offering. Otezla brou [Read more]
IMPACT SNAPSHOT
EVENT TIME:
AMGN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS